Bristol-Myers Squibb

Ambrx names Peter Kiener chief scientific officer

Wednesday, August 28, 2013 02:42 PM

Ambrx, a clinical stage biopharmaceutical company, has appointed Peter Kiener, Ph.D., chief scientific officer. Kiener has experience in the development of next-generation biologic therapeutics, including multi-specific, antibody based biologics, while president, chief executive officer and cofounder of Zyngenia.

Kiener led Zyngenia through its early stages of development, including validating the technology platform, identifying and advancing lead programs and securing Series A funding. Previously, Kiener was the executive vice president and global head of biologics R&D at MedImmune, AstraZeneca's biologics arm. He built protein and antibody engineering capabilities and oversaw the submission of multiple INDs and NDAs. Over the previous 18 years, Kiener held multiple positions at Bristol-Myers Squibb, 10 of which were spent working on biological therapeutics.

More... »

Ashfield names Michael Burman VP Medical Call Center

Monday, August 19, 2013 08:48 AM

Ashfield, part of United Drug, has named Dr. Michael Burman vice president of its Ivyland, Pa-based Medical Call Center. Ashfield Medical Information, formerly Alliance Healthcare, is a provider of medical information and pharmacovigilance call center services to healthcare, biotech and device companies.

More... »

inVentiv Health Clinical expands executive team

Friday, August 9, 2013 02:02 PM

CRO inVentiv Health Clinical has appointed Dawn Anderson president of phase II-IV development, Martin Birkhofer chief medical officer and Richard Shimota chief financial officer.

More... »

Moderna Therapeutics names Joseph Bolen president of R&D

Thursday, August 1, 2013 12:27 PM

Moderna Therapeutics, developing messenger RNA therapeutics, a new treatment modality to enable the in vivo production of therapeutic proteins, has hired Joseph Bolen, Ph.D., as its president of R&D.

More... »

Verified Clinical Trials partners with SAFE-BioPharma

Friday, July 26, 2013 09:00 AM

Verified Clinical Trials, whose technology helps eliminate multiple enrollments by clinical trial volunteers and provides Medicare Secondary Payer Law compliance strategies, will offer its services with SAFE-BioPharma, a global digital identity management and signature standard used by many of the world’s largest biopharmaceutical companies. The company also has joined the SAFE-BioPharma Vendor Partner program, providing it with direct access to decision-makers in SAFE-BioPharma’s member companies.

More... »

Bristol-Myers Squibb to create 579 jobs

Friday, July 19, 2013 02:40 PM

Bristol-Myers Squibb will open a North America capability center and create 579 life sciences jobs in Tampa, Fla. The 70,000-square-foot facility will open in January 2014 with approximately 250 employees. The company will add more than 325 additional jobs by 2017.

More... »

Boston-based Alzheimer's disease research highlighted at Alzheimer's Association International Conference 2013

Tuesday, July 16, 2013 09:35 AM

Three studies reported at the Alzheimer's Association International Conference 2013 (AAIC) demonstrate the vitality and diversity of Alzheimer's disease research being conducted in Boston, the host city for this year's conference.

More... »

InnovoCommerce, SAFE-BioPharma collaborate

Friday, June 28, 2013 02:02 PM

The global SAFE-BioPharma digital identity and signature standard is being incorporated into the InnovoCommerce eClinical product suite used by pharmaceutical companies for their enterprise and investigator portal initiatives. InnovoCommerce is a source of eClinical collaboration products and solutions. It also has joined SAFE-BioPharma Association’s Vendor Partner program.

More... »

Biogen Idec, WPI to develop programs for BETC

Friday, May 31, 2013 10:50 AM

Global biotechnology company Biogen Idec has signed a collaboration agreement with Worcester Polytechnic Institute (WPI) to develop and deliver programs at the university’s Biomanufacturing Education and Training Center (BETC) of Worcester, Mass.

More... »

Adaptive, BMS ink biomarker discovery collaboration agreement

Wednesday, May 15, 2013 11:57 AM

Adaptive Biotechnologies, a Seattle-based developer of next generation sequencing assays, has entered into a collaboration agreement with Bristol-Myers Squibb for the discovery of immunological biomarkers in oncology.

More... »